| PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma (NCT07209059) | National Research Center for Hematology, Russia | 2025-07-29 |
| An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders (NCT06721598) | National Research Center for Hematology, Russia | 2025-01-09 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders (NCT06705530) | National Research Center for Hematology, Russia | 2024-11-26 |
| IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML (NCT06418776) | National Research Center for Hematology, Russia | 2024-04-01 |
| MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients (NCT06237192) | National Research Center for Hematology, Russia | 2023-04-01 |
| Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL (NCT06188676) | National Research Center for Hematology, Russia | 2022-04-01 |
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis (NCT05158608) | National Research Center for Hematology, Russia | 2022-01-01 |
| Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination (NCT05165719) | National Research Center for Hematology, Russia | 2021-07-07 |
| RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL (NCT05425654) | National Research Center for Hematology, Russia | 2021-05-17 |
| The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission (NCT05339204) | National Research Center for Hematology, Russia | 2021-02-01 |
| Registry of Patients With Hematologic Disease and COVID-19 in Russia (NCT04422470) | National Research Center for Hematology, Russia | 2020-06-22 |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (NCT04578847) | National Research Center for Hematology, Russia | 2020-01-15 |
| Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma (NCT05660993) | National Research Center for Hematology, Russia | 2019-08-19 |